ARCHIVES

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

This article is from The Cancer Letter archive.

Vol. 33 No. 46 | December 14, 2007

Download PDF Visit The Full Archive

Related Articles

Patient Harm—Including One Death—Cited As Faculty Challenges MD Anderson Leadership

September 20, 2013

Wynder, Weinburg Head Recipients Of Milken Awards

December 14, 1990

Bristol No Longer Needs Yew From Public Lands, Official Says; Will Use Processed Needles

January 29, 1993

Editorial: A Record-Breaking Year for The Cancer Letter

December 19, 2014

Navelbine+Herceptin: 78% Response In Breast Cancer

November 29, 2002

FDA Advisors: DepoCyt May Test Accelerated Approval Mechanism

November 27, 1998